Risk for fungal infections doubles with corticosteroid use vs. TNF-a inhibitors in IBD

May 21, 2022

SAN DIEGO — Corticosteroid use should be minimized in patients with inflammatory bowel disease to reduce the risk for invasive fungal infections, according to research presented at Digestive Disease Week 2022.“We know that the immunosuppressants used to treat IBD increase the risk for infection and multiple studies have shown that corticosteroids are by far the worst agents,” Martin H. Gregory, MD, of the division of gastroenterology at Washington University School of Medicine in St. Louis, said. “There hasn’t been a large scale, systematic study to see what riskRead More

Categories: News

TNF inhibitors less effective for older-onset IBD patients

Anti-tumor necrosis factor therapy had reduced efficacy and safety for bio-naive patients with older-onset inflammatory bowel disease compared with younger patients, according to a study…

May 12, 2022

Hispanic patients with IBD at increased risk for hospitalization, surgery

Hispanic patients treated with biologic agents for inflammatory bowel diseases face a greater risk for hospitalization, surgery and infections compared with non-Hispanic patients, according to…

July 13, 2022

Vedolizumab, ustekinumab best anti-TNF for infection risk in older adult IBD

SAN DIEGO — Vedolizumab and ustekinumab associated with a lower risk for infection-related hospitalizations compared with anti-tumor necrosis factor agents in patients who initiated inflammatory…

May 31, 2022

TNF inhibitors pose ‘modest risk’ for new-onset psoriasis

Patients with immune mediated diseases and treated with tumor necrosis factor-alpha inhibitors have a modest risk for new onset psoriasis, according to a study.“Biologics are…

July 15, 2022

Navigating the Legislative Tides: A Mid-Session Update from the Florida Gastroenterologic Society

As the 2024 Legislative Session in Florida strides past its one-third mark, the Florida Gastroenterologic Society (FGS) remains actively engaged, monitoring and influencing healthcare legislation that impacts gastroenterologists across the state. While thousands of bills are in the mix, only a select few have garnered significant attention. Here’s a concise overview of the key bills and initiatives that FGS is closely watching:

Justin Bouck January 30, 2024

Related Articles